key: cord-0686577-1reh3qvb
authors: Han, Henry; Chung, Grace; Sippola, Emily; Chen, Wilson; Morgan, Spencer; Renner, Elizabeth; Ruff, Allison; Sales, Anne; Kurlander, Jacob; Barnes, Geoffrey D.
title: Improving preprocedure antithrombotic management: Implementation and sustainment of a best practice alert and pharmacist referral process
date: 2021-07-16
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12558
sha: fdbc456f17e6f11b5bfd8b15a984ef1fcf1539c3
doc_id: 686577
cord_uid: 1reh3qvb

BACKGROUND: Electronic medical record–based interventions such as best practice alerts, or reminders, have been proposed to improve evidence‐based medication prescribing. Formal implementation evaluation including long‐term sustainment are not commonly reported. Preprocedural medication management is often a complex issue for patients taking antithrombotic medications. METHODS: We implemented a best practice alert (BPA) that recommended referral to an anticoagulation clinic before outpatient elective gastrointestinal (GI) endoscopies. Eligible patients were taking an oral anticoagulant (warfarin or direct oral anticoagulant [DOAC]) and/or antiplatelet medications. Patients referred to the anticoagulation clinic were compared to those managed by the ordering provider. Outcomes assessed included guideline‐adherent drug management before endoscopy, documentation of a medication management plan, guideline‐adherent rates of bridging for high‐risk patients taking warfarin, and evaluation for sustained use of BPA. RESULTS: Eighty percent of patients (553/691) were referred to the anticoagulation clinic during the initial 13‐month study period. Most referrals came from gastroenterologists (397/553; 71.8%) followed by primary care providers (127/554; 22.9%). Patients referred had improved rates of guideline‐adherent medication management compared to those who were not referred (97.4% vs 91.0%; P = .001). Documentation of medication plan was significantly higher in the referred group (99.1% vs 59.4%; P ≤ .001). There were no differences in rates of appropriate bridging for patients taking warfarin. Implementation of the BPA also resulted in sustained, consistent use over an additional 18 months following the initial study period. CONCLUSION: Implementation of a BPA before elective outpatient GI endoscopies was associated with improved rates of guideline‐adherent medication management and documented management plan, while streamlining preprocedural medication management.

• Preprocedural management of antithrombotic medications is complex.

• Implementing a referral process to an anticoagulation clinic improved medication management.

• The referral assisted with management of all oral anticoagulants and antiplatelet medications.

• Documentation of the preprocedure plan was improved with the referral process.

• Use of this referral process was sustained across >2 years following implementation.

Variation in medication prescribing is a common and complex quality of care delivery challenge. This is particularly true for clinical scenarios with robust evidence on how best to safely and effectively use medication therapy to reduce disease morbidity and/or mortality. Examples include underuse of lipid-lowering statin therapies in patients with known cardiovascular disease, 1,2 underuse of aldosterone antagonists in heart failure, [3] [4] [5] and overuse of antibiotics for patients with acute respiratory infections. 6 Electronic medical record (EMR) interventions have been proposed to reduce variation and improve quality of medication prescribing. While some have demonstrated improvement in evidence-based prescribing, 7 others have failed to achieve their goals. 8, 9 And few have been evaluated for multiyear sustained usage.

Antithrombotic medications, including anticoagulants, such as warfarin, apixaban, rivaroxaban, and dabigatran, and antiplatelet agents, such as clopidogrel, prasugrel, and ticagrelor, are commonly used to prevent thrombotic complications in patients with a variety of medical conditions, including atrial fibrillation, venous thromboembolism, coronary artery disease, peripheral arterial disease, and mechanical heart valves. Despite their proven efficacy, they also pose significant risk of bleeding, especially during an invasive procedure. Coordinating preprocedure management of chronic antithrombotic medications often presents a clinical challenge for both patients and clinicians. Additionally, clinical decision making varies greatly between different clinicians and specialists and frequently does not follow evidence-based management. 10 Mismanagement of antithrombotic medications places patients at increased risk of potentially life-threatening bleeding and/or thromboembolic complications (blood clots). It also leads to last-minute procedural cancellations as well as patient and clinician dissatisfaction. 11 We used gastrointestinal (GI) endoscopy procedures as an exemplary case study to test an EMR-based intervention. Specifically, we developed and implemented an automated EMR best practice alert (BPA), or reminder, and referral process to a dedicated anticoagulation clinic for patients taking chronic antithrombotic medications before their elective outpatient GI endoscopy procedures. We evaluated key implementation process outcomes, guideline-adherent medication management, and sustained usage of this EMR-based alert and referral process.

A new BPA and anticoagulation clinic referral process was implemented within our EMR system (Epic) starting in November 2017 as a pilot in one gastroenterology clinic and one primary care clinic in a single health care system in a Midwestern state in the United States. 12 It was gradually expanded over the subsequent 5 months until it was implemented system-wide in April 2018. This BPA ( Figure   S1 ) is triggered when an outpatient elective GI endoscopy procedure is ordered in the EMR for a patient listed as taking an oral anticoagulant or an antiplatelet medication (other than aspirin). The BPA recommends referral for preprocedural antithrombotic medication management by a clinical pharmacist within the health system's anticoagulation clinic. The ordering physician has the option to accept or decline the referral. If a referral is made to the anticoagulation clinic, a clinical pharmacist reviews the medical record, including date of procedure, type of antithrombotic medication, and comorbidities to assess for optimal preprocedure management. Preprocedure management, including if and when to stop the antithrombotic medication and the need for any short-acting "bridging" heparin anticoagulant, is determined using institutional guidelines (Tables S1 and S2). These institutional guidelines were adapted from national society guidelines and endorsed by clinical leaders within the health system. This plan is documented within the EMR, and a copy is sent to the ordering provider/primary care physician, cardiologist, and/ or gastroenterologist for review. If the patient does not fall clearly within guideline management for issues such as thrombotic risk and documented management plan, while streamlining preprocedural medication management.

anticoagulation, anticoagulation clinic, endoscopy, pharmacist, preprocedure management, quality improvement assessment, bleed risk assessment, or necessity of "bridging" heparin, then the pharmacists will reach out to the physicians or providers for input and consensus on best management strategy. Plans are reviewed and created typically more than 1 to 2 weeks before the procedure date to allow for sufficient time for changes to antithrombotic cessation plan if necessary.

An additional 0.6 full-time equivalent (FTE) pharmacist was added to help with increased workload. Pharmacists received instructions using health system-approved guidelines in addition to relying on their general pharmacotherapy training.

Eligible patients were at least 18 years old and taking either an anticoagulant medication (warfarin, apixaban, rivaroxaban, or dabigatran) or an antiplatelet agent (clopidogrel, prasugrel, or ticagrelor) who were also ordered for outpatient elective GI endoscopy. Patients were taken from a study period between November 1, 2017, and December 31, 2018. Relevant diagnoses of atrial fibrillation, venous thromboembolism, coronary artery disease, peripheral arterial disease, and mechanical heart valve were included in this study. Patients were excluded from the study if they were not taking an anticoagulant or antiplatelet medication before the GI endoscopic procedure, if they needed inpatient or urgent/emergent endoscopy, or if they were taking only aspirin. For the full list of exclusion criteria, please see the supplemental appendix.

The primary process outcome is the effect of the BPA on appropriate guideline-adherent medication management, where the key independent variable is whether the patient was referred or not.

Appropriateness was defined as correct drug discontinuation datetypically 7 days before the procedure for prasugrel; 5 days before the procedure for warfarin, clopidogrel, and ticagrelor; and 2 days before the procedure for apixaban, rivaroxaban, and dabigatran-and whether short-acting bridging heparin was required in accordance with institutional periprocedural medication management guidelines (Tables S1 and S2). The secondary outcome was documentation of a medication management plan within the EMR before endoscopy. We also explored sustainment of this implementation effort by assessing the number and proportion of BPAs that resulted in anticoagulation clinic referrals between November 2017 and June 2020, >2.5 years after the BPA was introduced.

We evaluated the association between patient-, provider-, and procedure-level characteristics and referral patterns to anticoagulation clinic. Patient factors of interest included diagnosis for antithrombotic therapy, type of antithrombotic medication taken, age, sex, type of procedure, concurrent use of aspirin, and prior endoscopic procedures as documented in EMR. Providerlevel characteristics included specialty of referring provider (defined as cardiology, gastroenterology, primary care, or other), and whether previous encounter with this BPA showed an increased pattern of referral from those same providers. Procedure-level characteristics include the duration of time (days) between the start of BPA implementation (November 2017) and the actual date of endoscopy.

To assess the sustainment of our implementation effort, the frequency of BPAs and percentage that resulted in anticoagulation clinic referral were assessed both in the primary study period (November 2017 to December 2018) and for an additional 18 months (through June 2020).

We used the Pearson chi-squared test to examine differences in referral to an anticoagulation clinic according to patient-, provider-, and procedure-level characteristics. A multilevel logistic regression model was constructed including all predictors that were significant in bivariate logistic regression analyses (diagnosis and type of medication at the patient level, specialty at the provider level). The multilevel model accounted for clustering at the provider level using provider identifier as a random effects variable. Trend analysis was performed for the outcomes of appropriate preprocedure medication discontinuation and documentation over the study period using multilevel logistic regression. Bivariate analyses were conducted to compare the anticoagulation management outcome measures of patients who did and did not get referral after the BPA for documentation of preprocedure management plan in chart, appropriate drug discontinuation before endoscopy, and appropriate bridging. All statistical analyses were performed using Stata/SE16.0 (StataCorp, College Station, TX, USA).

A waiver of informed consent was approved by the institutional review board for this project given the retrospective nature of the data collection. Table 1 . There were no significant differences between patients who were referred or not with regard to age, sex, concurrent use of aspirin, type of medication, and diagnosis. during the study period were more likely to place a referral than those who saw the BPA only once.

As shown in Table 1 , referral patterns were similar between different GI endoscopic procedure types of colonoscopy/flexible TA B L E 1 Association between patient-, provider-, and procedure-level characteristics and referral to anticoagulation clinic 

Guideline-adherent medication discontinuation pre-procedure was more common in the patient referred to the anticoagulation clinic than those not referred (97.4% vs 91.0%; P = .001; Table 2 ).

Patients referred to the anticoagulation clinic were more likely to have documentation of their preprocedure medication management plan than those not referred (99.1% vs 59.4%; P < .001). Both findings persisted in the multivariable logistic regression analyses (Table S3) . Despite a numerical difference in the percent of patients receiving appropriate bridging management before endoscopy in the referral and nonreferral groups, this did not meet statistical significance ( Table 2) .

Post-BPA implementation, there was no observed difference over time in the rates of guideline-adherent drug discontinuation and the proportion of patients with appropriate documentation between January and December 2018 (P trend > .50 for both; Figure 1 ).

Both the total number of BPA fires and proportion of those BPAs leading to an anticoagulation clinic referral were sustained over a 

We successfully implemented a system-wide BPA recommending anticoagulation clinic referral before elective GI endoscopy procedure for patients taking antithrombotic medications. Use of the referral process was high and sustained for >2.5 years. Implementation of the BPA and pharmacists' referral process improved preprocedure anticoagulation management and documentation, reducing variation in care.

Our study found that implementation of a BPA and anticoagulation clinic referral was associated with improved rates of guideline-adherent antithrombotic medication management. This workflow, such as for prenatal maternal vaccination and uncontrolled hypertension within outpatient visits, resulted in improved patient-associated outcomes. 18, 19 Second, the BPA design included the principle "make the right thing to do the easy thing to do." By automatically alerting clinicians at the time an endoscopy was ordered and preselecting the option for referral, the clinicians only had to "accept" the referral offer on the BPA for the process to begin. If they wanted to decline the referral, they had to use a few extra "clicks." In this way, the path of least resistance encouraged use of the anticoagulation clinic pharmacists and TA B L E 2 Association between referral to anticoagulation clinic and anticoagulation management outcomes increased the likelihood of evidence-based medication management.

This has been previously shown to be an effective method in inpatient tobacco counseling with "opting out" as the default for an automatic BPA, for both patient-level outcomes and hospital-level performance measures. 20 These design principles likely contributed both to the broad adoption of this care pathway and to its sustained use for nearly 2 years.

While this BPA used GI endoscopy as the exemplary case for implementation, this system could be expanded to include other outpatient elective procedures as well, such as lumbar puncture, thoracentesis, and elective cardiac procedures. In the United States, nearly two-thirds of anticoagulation clinics already use pharmacists and would be ideally positioned to provide preprocedure antithrombotic medication management if the appropriate guidelines and protocols were enacted. 15 Furthermore, other clinics that have explored this preprocedure management process have found it to be feasible. 21 As described previously, a diverse group of stakeholders was intimately involved in the development and pilot of this process. 12 While our system did require additional FTE pharmacist effort to handle the additional volume, we have previously shown that fewer cancellations resulting from this referral and review process would result in significant cost savings to the hospital system and would more than cover the additional costs. 12

First, implementation of this BPA was done at a single academic university health center, so outcomes may not be generalizable to other health centers. Additionally, we used our institutional guidelines would be small given that most patients using DOAC and antiplatelet medications were not routinely followed by the anticoagulation clinic.

Finally, while we are able to report on robust implementation and process outcomes, we are unable to report on clinical adverse event rates associated with the BPA and referral process.

Implementation of a BPA recommending referral to an anticoagulation clinic before elective GI endoscopic procedures in patients taking antithrombotic medications was associated with improved rates of documented medication management plan within the EMR as well as improved rates of guideline-adherent medication management. Furthermore, this referral process streamlined preprocedural antithrombotic medication management and showed consistent, sustained adoption over >2 years' time.

F I G U R E 2 Best practice alert (BPA) use and anticoagulation clinic referral over time

Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the Department of Veterans Affairs

Underuse of effective cardiac medications among women, middle-aged adults, and racial/ ethnic minorities with coronary artery disease (from the National Health and Nutrition Examination Survey

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012

Outpatient antibiotic prescribing for acute respiratory infections during influenza seasons

Practices to prevent venous thromboembolism: a brief review

High-priority drug-drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: override appropriateness and adverse drug events

Assessing the safety of electronic health records: a national longitudinal study of medication-related decision support

Bridging anticoagulation before colonoscopy: results of a multispecialty clinician survey

Periprocedural antithrombotic management from a patient perspective: a qualitative analysis

Assessment of a best practice alert and referral process for preprocedure antithrombotic medication management for patients undergoing gastrointestinal endoscopic procedures

Reimagining anticoagulation clinics in the era of direct oral anticoagulants

Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy

Structure and function of anticoagulation clinics in the United States: an AC forum membership survey

Structure and function of a perioperative anticoagulation management clinic

Evidence-based usability design principles for medication alerting systems

Association of a best-practice alert and prenatal administration with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination rates

Effectiveness of a best practice alerts at improving hypertension control

Effectiveness of an optout electronic heath record-based tobacco treatment consult service at an urban safety net hospital

Using health systems engineering approaches to prepare for tailoring of implementation interventions

Improving preprocedure antithrombotic management: Implementation and sustainment of a best practice alert and pharmacist referral process

HH and GB contributed equally to the writing of this manuscript.HH, WC, and SM contributed to data collection. HH, GB, and GC contributed to data analysis. All authors contributed to manuscript review and revisions.

GB discloses consulting fees from Pfizer/Bristol-Myers Squibb, Janssen, AMAG Pharmaceuticals, and Acelis Connected Health. All other authors declare no conflicts of interest.

https://orcid.org/0000-0003-4911-1070

Jacob Kurlander @Jekurlander Geoffrey D. Barnes @GBarnesMD